KR20220090815A - Composition for preventing or improving skin cell damage caused by ultraviolet rays containing Symplocos chinensis f. pilosa (Nakai) Ohwi fruits extracts - Google Patents
Composition for preventing or improving skin cell damage caused by ultraviolet rays containing Symplocos chinensis f. pilosa (Nakai) Ohwi fruits extracts Download PDFInfo
- Publication number
- KR20220090815A KR20220090815A KR1020200181700A KR20200181700A KR20220090815A KR 20220090815 A KR20220090815 A KR 20220090815A KR 1020200181700 A KR1020200181700 A KR 1020200181700A KR 20200181700 A KR20200181700 A KR 20200181700A KR 20220090815 A KR20220090815 A KR 20220090815A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- cell damage
- norinjae
- ultraviolet rays
- preventing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 210000004927 skin cell Anatomy 0.000 title claims abstract description 35
- 239000000284 extract Substances 0.000 title claims abstract description 29
- 230000005779 cell damage Effects 0.000 title claims abstract description 23
- 208000037887 cell injury Diseases 0.000 title claims abstract description 22
- 235000013399 edible fruits Nutrition 0.000 title claims description 11
- 244000022370 Symplocos paniculata Species 0.000 title description 3
- 235000003337 Symplocos paniculata Nutrition 0.000 title description 3
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 16
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 7
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 7
- 108010050808 Procollagen Proteins 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 2
- 101710108790 Stromelysin-1 Proteins 0.000 claims description 2
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 230000003064 anti-oxidating effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000010269 ABTS assay Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000007845 reactive nitrogen species Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CCTFAOUOYLVUFG-UHFFFAOYSA-N 2-(1-amino-1-imino-2-methylpropan-2-yl)azo-2-methylpropanimidamide Chemical compound NC(=N)C(C)(C)N=NC(C)(C)C(N)=N CCTFAOUOYLVUFG-UHFFFAOYSA-N 0.000 description 1
- NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 1
- -1 ABTS cation Chemical class 0.000 description 1
- 244000119012 Bequaertiodendron magalismontanum Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 노린재나무 추출물을 포함하는 자외선에 의한 피부세포 손상의 예방 또는 개선용 조성물 또는 항산화용 조성물에 관한 것으로, 본 발명은 자외선에 의해 손상된 피부 세포의 효과적으로 회복시켜줄 수 있는 노린재나무 추출물 및 이를 유효성분으로 포함하는 약학적 조성물, 화장료 조성물 또는 식품 조성물을 제공할 수 있다. The present invention relates to a composition for preventing or improving skin cell damage caused by ultraviolet rays or an antioxidant composition comprising the Norinjae tree extract, and the present invention relates to a Norinjae tree extract, which can effectively restore skin cells damaged by ultraviolet rays, and effective the same It is possible to provide a pharmaceutical composition, cosmetic composition or food composition comprising as a component.
Description
본 발명은 자외선에 의한 피부세포 손상의 예방 또는 개선용 조성물에 관한 것으로, 구체적으로는 노린재나무 열매 추출물을 포함하는 자외선에 의한 피부세포 손상의 예방 또는 개선용 조성물에 관한 것이다. The present invention relates to a composition for preventing or improving skin cell damage caused by ultraviolet rays, and more particularly, to a composition for preventing or improving skin cell damage caused by ultraviolet rays, comprising an extract from the fruit of Norinjae tree.
피부노화는 요인에 따라 내인성 노화(Intrinsic aging)와 외인성 노화 (Extrinsic aging)로 구분할 수 있다. 내인성 노화는 나이에 따른 피부 표피 및 진피의 생리적 기능 변화가 원인이며, 외인성 노화는 대기오염, 자외선 노출, 스트레스 등의 환경으로부터 발생하는 피부의 생리적 기능 변화가 원인으로 알려져 있다. 이러한 노화의 메커니즘 중 UV에 의해 유도되는 산화적 스트레스 (Oxidative Stress)는 체내의 자유라디칼(Free Radical)을 증가시키고, 콜라겐(Collagen)을 분해하는 MMP-1의 활성 증가 및 히아루론산 (Hyaluronic acid)을 분해는 히아루론라제(Hyaluronidase)의 활성 증가로 피부 표피 및 진피 손상을 야기한다.Skin aging can be divided into intrinsic aging and extrinsic aging according to factors. It is known that intrinsic aging is caused by changes in the physiological functions of the skin epidermis and dermis according to age, and extrinsic aging is caused by changes in the physiological functions of the skin caused by environmental factors such as air pollution, UV exposure, and stress. Among these mechanisms of aging, oxidative stress induced by UV increases free radicals in the body, increases the activity of MMP-1 that decomposes collagen, and reduces hyaluronic acid. Decomposition causes damage to the epidermis and dermis of the skin due to increased activity of hyaluronidase.
일상생활에서 우리는 햇빛에 항상 노출되어 있으며, 특히 UV-B 노출로 인해 발생하는 세포의 손상 및 피부암 유발은 일상생활에서 피할 수 없는 요소이다.In our daily life, we are always exposed to sunlight, and in particular, cell damage and skin cancer caused by UV-B exposure are unavoidable factors in our daily life.
이에 따른 UV 노출에 의한 피부세포손상 억제에 대한 기전 연구가 활발히 진행되어 왔으며 생화학적 효능, 효과를 나타내는 화장료 및 건강기능식품, 의약품에 대한 연구가 활발히 진행되고 있다. 연구수준의 발달 및 기술력증가로 실질적인 효능, 효과를 가진 소재들이 주 연구 대상이다.As a result, studies on the mechanism of suppression of skin cell damage caused by UV exposure have been actively conducted, and studies on cosmetics, health functional foods, and pharmaceuticals showing biochemical efficacy and effects are being actively conducted. Materials with practical efficacy and effects are the main research subjects due to the development of the research level and the increase in technology.
노린재나무(Symplocos chinensis f. pilosa (Nakai) Ohwi)는 노린재나무과(Symplocaceae)로 중국, 일본, 인도에 분포하며 우라나라 각처의 산과 들에 나는 낙엽 관목으로 키는 1-3m로 자라며 가지는 퍼지고, 작은 가지에는 털이 있다. 잎은 호생이며 난형 또는 긴 타원상 난형으로 양 끝이 뾰족하고, 보통 가장자리에 작은 톱니가 있으나 때로는 뚜렷하지 않고 호생하며 표면은 짙은 녹색이고 털이 없으며, 뒷면은 연두색으로 털이 있거나 없다. 열매는 길이 8mm로서 타원형이고 9월에 벽색(碧色)으로 익는다. 원추화서는 길이 4~8cm로서 새로 난 가지 끝에 달리며 화경에 털이 있고 꽃잎은 긴 타원형이며 옆으로 터진다. 꽃은 지름 8~10mm이고 5월에 백색으로 핀다. 꽃잎은 장타원형으로 수술이 많고 약 보름간 감상할 수 있으며 은은한 향기가 있다. Symplocos chinensis f. pilosa (Nakai) Ohwi is a Symplocos chinensis f. pilosa (Nakai) Ohwi, distributed in China, Japan, and India. The branches are hairy. Leaves are alternate, ovate or long oval-ovate, with sharp ends, usually with small saw teeth on the edge, but sometimes indistinctly and alternately. The fruit is 8mm long, oval, and ripens in a wall color in September. The panicle is 4-8cm long, hangs at the tip of a new branch, has hairs on the peduncle, and the petals are long oval and open to the side. Flowers are 8-10mm in diameter and bloom white in May. The petals are long oval, with many stamens, and can be enjoyed for about a fortnight and have a subtle fragrance.
노린재나무 추출물의 당뇨병, 당뇨합병증의 치료용, 신경계 진통 치료용 등에 대해서는 알려져 있으나 자외선에 의한 피부세포 손상의 예방 또는 개선할 수 있는 효과에 대해서는 알려져 있지 않아 노린재나무 추출물의 피부세포 손상의 예방 또는 개선용 소재로 개발하고자 하였다. It is known for the treatment of diabetes, diabetic complications, and nervous system analgesia, but the effect of preventing or ameliorating the skin cell damage caused by UV rays is not known. It was intended to be developed as a material for
상기와 같은 문제점을 해결하기 위해 본 발명은 피부 세포 손상의 예방 또는 개선에 효과적인 노린재나무 추출물을 제공하고자 한다.In order to solve the above problems, the present invention is to provide an extract of Norinjae tree effective for preventing or improving skin cell damage.
또한, 상기 노린재나무 추출물을 포함하는 피부 세포 손상의 예방 또는 개선용 조성물을 제공하고자 한다. In addition, it is intended to provide a composition for preventing or improving skin cell damage comprising the Norinjae tree extract.
또한, 상기 노린재나무 추출물을 포함하는 항산화용 조성물을 제공하고자 한다.In addition, it is intended to provide an antioxidant composition comprising the Norinjae tree extract.
상기와 같은 목적을 달성하기 위해 본 발명은 노린재나무 추출물을 제공한다.In order to achieve the above object, the present invention provides a Norinjae tree extract.
또한, 상기 노린재나무 추출물을 포함하는 피부 세포 손상의 예방 또는 개선용 조성물을 제공한다.In addition, it provides a composition for preventing or improving skin cell damage comprising the Norinjae tree extract.
또한, 상기 노린재나무 추출물을 포함하는 항산화용 조성물을 제공한다.In addition, there is provided an antioxidant composition comprising the Norinjae tree extract.
본 발명에 있어서, 상기 자외선에 의한 인간 피부세포 손상은 자외선 노출에 의해 생기는 인간 표피세포 및 진피 세포 손상인 것을 특징으로 하는 자외선에 의한 인간 피부세포 손상 예방 및 개선용 조성물을 제공한다. In the present invention, there is provided a composition for preventing and improving human skin cell damage due to ultraviolet light, characterized in that the damage to human skin cells by ultraviolet rays is damage to human epidermal cells and dermal cells caused by exposure to ultraviolet rays.
구체적으로는 인간 표피세포 및 진피세포에서 자외선에 의한 세포 손상을 복구시킬 뿐만 아니라, 자외선에 의해 감소되는 MMP-1, MMP-2, MMP-3, MMP-9 또는 pro-collagen(프로콜라겐)의 발현량을 정상군 수준으로 회복시킬 수 있다.Specifically, it not only repairs cellular damage caused by UV rays in human epidermal cells and dermal cells, but also reduces the amount of MMP-1, MMP-2, MMP-3, MMP-9 or pro-collagen (procollagen) that is reduced by UV rays. The expression level can be restored to the level of the normal group.
본 발명에 있어서, 인간 피부세포의 “손상”이란 자외선에 의한 인간 피부세포의 사멸, 피부 세포 DNA 손상, 활성산소종 증가, 지질과산화 증가 등을 포함하며, 그 증상으로는 홍반, 일광화상, 색소침착, 광노화, 피부암 등을 포함할 수 있다. 또한, 손상의“예방”은 상기 자외선에 의한 피부세포의 손상을 억제시키거나 지연시키는 모든 행위를 의미한다. 또한, 손상의 “개선”은 상기 자외선에 의한 피부세포의 손상 상태의 완화 또는 증상의 정도를 감소시키는 모든 행위를 의미한다.In the present invention, "damage" of human skin cells includes apoptosis of human skin cells by ultraviolet rays, DNA damage of skin cells, increase in reactive oxygen species, increase in lipid peroxidation, and the like, and the symptoms include erythema, sunburn, pigmentation. deposition, photoaging, skin cancer, and the like. In addition, “prevention” of damage refers to any action that inhibits or delays the damage to skin cells by the ultraviolet rays. In addition, "improvement" of damage refers to any action of alleviating the damage state of the skin cells caused by the ultraviolet rays or reducing the degree of symptoms.
상기 자외선은 UV-A, UV-B 등을 포함하고, 이에 제한되는 것은 아니다.The ultraviolet rays include, but are not limited to, UV-A and UV-B.
상기 항산화는 산화를 억제하는 작용을 의미하는 것으로, 인체는 산화촉진물질(prooxidant)과 산화억제물질(antioxidant)이 균형을 이루고 있으나 여러 가지 요인들에 의하여 이런 균형상태가 불균형을 이루게 되고 산화촉진 쪽으로 기울게 되면, 산화적 스트레스(oxidative stress)가 유발되어 잠재적인 세포손상 및 병리적 질환을 일으키게 된다. 이러한 산화적 스트레스의 직접적 원인이 되는 활성 산소종(reactive oxygen species, ROS)은 불안정하고 반응성이 높아 여러 생체물질과 쉽게 반응하고, 체내 고분자들을 공격하여 세포와 조직에 비가역적인 손상을 일으키거나 돌연변이, 세포독성 및 발암 등을 초래하게 된다.The antioxidant means the action of inhibiting oxidation, and although prooxidant and antioxidant are in balance in the human body, this balance is unbalanced by various factors and leads to oxidation promotion. When tilted, oxidative stress is induced, leading to potential cell damage and pathological diseases. Reactive oxygen species (ROS), the direct cause of oxidative stress, are unstable and highly reactive, so they easily react with various biomaterials and attack the body's polymers to cause irreversible damage to cells and tissues, mutations, or mutations. It causes cytotoxicity and carcinogenesis.
NO, HNO2, ONOO와 같은 활성 질소종(reactive nitrogen species, RNS)은 염증 반응 시 대식세포 호중구 및 다른 면역 세포들의 면역반응으로 인해 다량 생성되며, 이때 ROS도 같이 생성된다. 상기와 같은 활성산소는 체내에서 세포를 산화시켜 파괴시키며, 그에 따라 각종 질환에 노출되게 된다. 또한, 상기 항산화는 세포 내 대사 또는 자외선의 영향으로 인한 산화적 스트레스에 따라 반응성이 높은 자유 라디칼 (free radical) 또는 활성 산소종(Reactive oxygen species, ROS)에 의한 세포의 산화를 억제하는 기능을 의미하며, 자유 라디칼 또는 활성 산소종을 제거하여 이로 인한 세포의 손상이 감소되는 것을 포함한다.Reactive nitrogen species (RNS) such as NO, HNO2, and ONOO are produced in large amounts due to the immune response of macrophages, neutrophils and other immune cells during the inflammatory response, and ROS is also generated at this time. The active oxygen as described above oxidizes and destroys cells in the body, and thus is exposed to various diseases. In addition, the antioxidant refers to the function of inhibiting oxidation of cells by highly reactive free radicals or reactive oxygen species (ROS) depending on intracellular metabolism or oxidative stress caused by the influence of ultraviolet rays. and removing free radicals or reactive oxygen species, thereby reducing cell damage.
또한, 본 발명에서의 항산화 효과는 ABTS, DPPH와 같은 자유라디컬 소거 능력, ORAC, ROS와 같은 활성산소 억제능 또는 제거능을 포함한다. In addition, the antioxidant effect in the present invention includes the ability to scavenging free radicals such as ABTS and DPPH, and the ability to inhibit or remove active oxygen such as ORAC and ROS.
상기 노린재나무 추출물은 식물 전체를 추출하여 얻어진 것이거나, 식물 일부(뿌리, 잎, 꽃, 줄기 열매 등), 예컨대 식물이 지상부(잎, 꽃, 줄기, 열매 등), 바람직하게는 줄기, 잎, 열매를 추출하여 얻어진 것일 수 있고, 더욱 바람직하게는 노린재나무 열매 추출물 일 수 있으나 이에 한정되는 것은 아니다. The Norinjae extract is obtained by extracting the whole plant, or a part of the plant (root, leaf, flower, stem fruit, etc.), such as the above-ground part of the plant (leaf, flower, stem, fruit, etc.), preferably the stem, leaf, It may be obtained by extracting the fruit, and more preferably may be a Norinjae fruit extract, but is not limited thereto.
상기 노린재나무 추출물은 종래에 천연식물을 추출하기 위하여 이용된 어떠한 용매로 추출될 수 있으며, 바람직하게는 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매로 추출될 수 있다. 상기 알코올은 에탄올, 메탄올, 이소프로판올, 및 부탄올 등으로 이루어진 군에서 선택된 어느 하나 이상이 사용될 수 있으며, 바람직하게는 에탄올이 사용될 수 있다.The Norinjae tree extract may be extracted with any solvent conventionally used to extract natural plants, and preferably may be extracted with water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. As the alcohol, any one or more selected from the group consisting of ethanol, methanol, isopropanol, and butanol may be used, and ethanol may be preferably used.
상기 에탄올은 제한되는 것은 아니지만 30 내지 90%(v/v) 에탄올, 바람직하게는 60 내지 80%(v/v), 더욱 바람직하게는 70%(v/v) 에탄올이 사용될 수 있다.The ethanol is not limited, but 30 to 90% (v/v) ethanol, preferably 60 to 80% (v/v), more preferably 70% (v/v) ethanol may be used.
상기 조성물은 식품 조성물, 화장료 조성물, 약학적 조성물 중 선택되는 어느 하나일 수 있다. The composition may be any one selected from a food composition, a cosmetic composition, and a pharmaceutical composition.
상기 노린재나무 추출물이 식품 조성물, 화장료 조성물, 약학적 조성물에 포함될 경우, 그 농도는 제한되는 것은 아니지만 바람직하게는 0 초과 내지 500μg/ml, 더욱 바람직하게는 0.1 내지 300μg/ml, 더욱 바람직하게는 0.1 내지 100μg/m의 농도로 포함될 수 있다. 상기 범위를 초과할 경우, 피부 손상의 예방 또는 개선효과가 크게 개선되지 않는다. When the Norinjae tree extract is included in a food composition, a cosmetic composition, or a pharmaceutical composition, the concentration is not limited, but preferably more than 0 to 500 µg/ml, more preferably 0.1 to 300 µg/ml, more preferably 0.1 to 100 μg/m may be included. When it exceeds the above range, the prevention or improvement effect of skin damage is not significantly improved.
상기 약학적 조성물은 당 업계에서 약학적 조성물을 제조할 때 일반적으로 제조되는 형태로 제조될 수 있으며, 정제, 과립제, 환제, 캡슐제, 액상형 등으로 제조될 수 있다. 또한, 상기 약학적 조성물은 당 업계에서 약학적 조성물을 제조할 때, 통상적으로 사용되는 첨가제, 부형제, 담체 등을 추가적으로 더 포함할 수 있다.The pharmaceutical composition may be prepared in a form generally prepared when preparing a pharmaceutical composition in the art, and may be prepared in the form of tablets, granules, pills, capsules, liquids, and the like. In addition, the pharmaceutical composition may further include additives, excipients, carriers, etc. commonly used in the art for preparing a pharmaceutical composition.
상기 화장료 조성물은 당 업계에서 화장료 조성물을 제조할 때 일반적으로 제조되는 형태로 제조될 수 있으며, 화장수, 크림, 로션 등을 형태가 그 예이다. 또한, 상기 화장료 조성물은 당 업계에서 화장료 조성물을 제조할 때 통상적으로 첨가되는 첨가제, 유화제, 계면활성제, 보습제, 방부제 등을 추가적으로 더 포함할 수 있다.The cosmetic composition may be prepared in a form that is generally prepared when manufacturing a cosmetic composition in the art, and examples include lotion, cream, lotion, and the like. In addition, the cosmetic composition may further include additives, emulsifiers, surfactants, humectants, preservatives, and the like, which are conventionally added when preparing a cosmetic composition in the art.
상기 식품 조성물은 당 업계에서 식품 조성물을 제조할 때 일반적으로 제조되는 형태로 제조될 수 있으며, 당 업계에서 화장료 조성물을 제조할 때 통상적으로 첨가되는 첨가제, 색소, 향료 등을 추가적으로 더 포함할 수 있다.The food composition may be prepared in a form generally prepared when preparing a food composition in the art, and may further include additives, pigments, fragrances, etc. that are commonly added when preparing a cosmetic composition in the art .
본 발명은 노린재나무 추출물을 포함하는 자외선에 의한 피부세포 손상의 예방 또는 개선용 조성물 및 항산화용 조성물에 관한 것으로, 본 발명은 자외선에 의해 손상된 피부 세포의 효과적으로 회복시켜줄 수 있는 노린재나무 추출물 및 이를 유효성분으로 포함하는 약학적 조성물, 화장료 조성물 또는 식품 조성물을 제공할 수 있다. The present invention relates to a composition for preventing or improving skin cell damage caused by ultraviolet rays and an antioxidant composition comprising the Norinjae tree extract, and the present invention relates to a Norinjae tree extract that can effectively restore skin cells damaged by ultraviolet rays and effective the same A pharmaceutical composition, cosmetic composition or food composition comprising as a component may be provided.
도 1은 본 발명에 따른 노린재나무 추출물이 처리된 피부세포에서 UV-B를 조사하고 이에 따른 MMP-1, -3, -9 발현 및 type-1 프로콜라겐 mRNA 발현 결과를 나타낸 것이다.1 shows the results of MMP-1, -3, -9 expression and type-1 procollagen mRNA expression according to UV-B irradiation in skin cells treated with Norinjae tree extract according to the present invention.
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by way of Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples and Experimental Examples.
<실시예> 노린재나무 추출물의 제조<Example> Preparation of Norinjae tree extract
노린재나무 열매 추출물로서 가을에 성숙된 노린재나무 열매를 수집하였다. 수집한 열매는 바로 분쇄하거나, 상온에서 음건하거나, 50℃ 건조기에서 건조한 것을 사용하였다. 추출 수율을 높이기 위해 건조한 종자를 분쇄기로 분쇄하였으며 추출 용매는 70%(v/v) 에탄올을 사용하여 추출하여 제조하였다.As an extract of Hemniferae tree fruit, mature Hemniferae fruit was collected in the fall. The collected fruits were immediately pulverized, dried in the shade at room temperature, or dried in a dryer at 50 ° C. To increase the extraction yield, dried seeds were pulverized with a grinder, and the extraction solvent was prepared by extraction using 70% (v/v) ethanol.
<실험예 1> UV-B 처리에 의한 세포내 Collagen, Matrix metalloprotease(MMP-1, -2, -3, -9), Tissue inhibitor of Metalloproteinases(TIMP-1, -2), Reversion-inducing-cysteine-rich protein(RECK) 등 피부 항노화 인자에 대한 활성 검정<Experimental Example 1> Intracellular Collagen by UV-B treatment, Matrix metalloprotease (MMP-1, -2, -3, -9), Tissue inhibitor of Metalloproteinases (TIMP-1, -2), Reversion-inducing-cysteine -Activity assay for skin anti-aging factors such as rich protein (RECK)
본 발명에 따른 노린재나무 추출물의 자외선에 의한 피부세포 손상의 예방 또는 개선효과를 확인하기 위해 피부 세포 내에서의 UV-B를 30mJ/cm2 로 조사하여 TIMP-1, -2, RECK 및 Collagen의 감소 및 MMP 활성을 효과적으로 억제하는지 확인하기 위해 실험을 진행하였다. In order to confirm the prevention or improvement effect of the Norinjae tree extract according to the present invention on the prevention or improvement of skin cell damage caused by UV rays, UV-B in the skin cells was irradiated at 30mJ/cm 2 to reduce TIMP-1, -2, RECK and Collagen An experiment was conducted to determine whether the reduction and MMP activity were effectively inhibited.
실시예의 노린재나무 추출물 각각 0, 4, 20, 100μg/ml씩 처리한 실험군에 UV-B를 30mJ/cm2 로 조사하여 MMP-1, -2, -3, -9 등의 발현량을 확인하였다. 그 결과, UV-B에 의해 감소되었던 MMP-1, -2, -3, -9의 발현량이 크게 증가하였고, 감소한 pro-collagen의 발현량 또한 크게 증가하였음을 확인하였다(도 1).The experimental group treated with 0, 4, 20, and 100 μg/ml of Norinjae tree extract of Example was irradiated with UV-B at 30 mJ/cm 2 to confirm the expression levels of MMP-1, -2, -3, -9, etc. . As a result, it was confirmed that the expression levels of MMP-1, -2, -3, and -9, which were reduced by UV-B, increased significantly, and the decreased expression level of pro-collagen was also significantly increased ( FIG. 1 ).
<실험예 2> 본 발명에 따른 노린재나무 추출물의 항산화능 평가<Experimental Example 2> Antioxidative activity evaluation of Norinjae tree extract according to the present invention
본 발명에 따른 노린재나무 추출물의 항산화능을 평가하기 위해 하기와 같이 항산화능 평가를 진행하였다. In order to evaluate the antioxidant capacity of the Norinjae tree extract according to the present invention, the antioxidant activity was evaluated as follows.
2-1. ABTS, DPPH, ORAC assay2-1. ABTS, DPPH, ORAC assay
ABTS assay: 7mM ABTS와 2.45 mM potassium persulfate를 섞고, 상온에서 16시간 incubation 후 ABTS 양이온 (ABTS+)을 형성시켰다. 그 후, 734 nm에서 흡광도의 값이 1.5 이하가 되도록 희석하여 시험용액으로 제조하였다. 앞서 만든 ABTS+ 용액 1ml에 시료 10μl을 가하여 흡광도 값을 5분 후에 측정하였다. ABTS assay: ABTS cation (ABTS + ) was formed after mixing 7mM ABTS and 2.45 mM potassium persulfate and incubating at room temperature for 16 hours. Thereafter, the test solution was prepared by diluting so that the absorbance value at 734 nm was 1.5 or less. 10 μl of the sample was added to 1 ml of the previously prepared ABTS + solution, and the absorbance value was measured after 5 minutes.
DPPH assay: 95% 에탄올에 용해시킨 0.4 mM DPPH 용액 0.8 ml에 시료 0.2ml을 첨가하여 혼합 후 암실에서 5분 동안 배양한 후 517nm에서 흡광도를 측정하였다. DPPH assay: 0.2 ml of sample was added to 0.8 ml of 0.4 mM DPPH solution dissolved in 95% ethanol, mixed, and then incubated for 5 minutes in the dark, and absorbance was measured at 517 nm.
ORAC assay: 우선, Peroxy radical의 생성을 위해 2,2'-azobis (2-methylpropionamidine) dihychloride (AAPH)를 사용하고, 표준물질로는 trolox를 사용하였다. 시료는 75mM phosphate buffer에 녹여 제조한 후 37℃에서 15분간 배양하였다. 그 후 시료 25μl에 0.2M 의 fluorescein을 150μl 첨가하고, 즉시 0.15nM AAPH 25μl을 첨가하였다. 그 후 60분간 (2분당 1회씩) 485nm-530nm 파장에서 측정하였다. 표준물질로 사용된 trolox의 농도를 0, 0.625, 1.25, 2.5, 5, 10, 20μM로 측정하여 시료의 저해 능력은 trolox equivalents로 표현하였다. ORAC assay: First, 2,2'-azobis (2-methylpropionamidine) dihychloride (AAPH) was used to generate peroxy radicals, and trolox was used as a standard material. The sample was prepared by dissolving it in 75 mM phosphate buffer, and then incubated at 37° C. for 15 minutes. After that, 150 μl of 0.2M fluorescein was added to 25 μl of the sample, and 25 μl of 0.15 nM AAPH was immediately added. After that, measurements were made at a wavelength of 485nm-530nm for 60 minutes (once every 2 minutes). The concentration of trolox used as a standard was measured as 0, 0.625, 1.25, 2.5, 5, 10, and 20 μM, and the inhibitory ability of the sample was expressed as trolox equivalents.
2-2. UV조사에 의한 피부 세포내 활성산소 (ROS) 과다 생성 억제효과 측정2-2. Measurement of inhibitory effect on excessive production of active oxygen (ROS) in skin cells by UV irradiation
피부세포에 UV 조사에 따라 발생하는 intracellular ROS는 DCFH-DA staining dye를 통해 측정하였다. DCFH-DA는 세포내로 신속하게 들어가는 형광 dye의 일종이며, 세포내 활성산소종이 증가하게 되면 DCFH-DA가 DCF-DA로 전환되며 초록색 형광값을 보이는 특성을 가진다. 세포를 배양한 후에 UV를 조사하고, 일정시간 더 배양한 후 배지를 제거하였다. 그 후 4 μM농도의 DCFH-DA를 HBS 에 녹여 세포에 처리하였다. 37℃에서 30분간 배양한 후, PBS로 3회 세척과정을 거쳤다. 그 후 FACs 의 FL-1 파장을 이용하여 형광값의 변화를 측정하였다. Intracellular ROS generated by UV irradiation on skin cells was measured using DCFH-DA staining dye. DCFH-DA is a type of fluorescent dye that rapidly enters the cell, and when reactive oxygen species in the cell increase, DCFH-DA is converted to DCF-DA and shows a green fluorescence value. After culturing the cells, UV was irradiated, and the medium was removed after further culturing for a certain period of time. Then, DCFH-DA at a concentration of 4 μM was dissolved in HBS and the cells were treated. After incubation at 37° C. for 30 minutes, it was washed three times with PBS. Thereafter, the change in fluorescence value was measured using the FL-1 wavelength of FACs.
2-3. UV 조사에 의한 피부 세포사멸 억제효과 측정2-3. Measurement of skin cell death inhibitory effect by UV irradiation
피부세포에 UV 조사에 따라 발생하는 세포사멸은 MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H-tetrazolium bromide) 시약을 이용하여 측정하였다. MTT 시약은 살아있는 미토콘드리아의 탈수소화효소에 의해 formazan을 형성하는데 형성된 formazan을 녹임으로써 세포사멸의 정도를 측정하였다. 세포를 배양한 후 UV를 조사한 후 일정시간 동안 배양한 후 배지를 제거하였다. 그 후 최종농도 0.5 mg/mL 농도의 MTT를 PBS 에 녹여 처리하였다. 37℃, 4시간 동안 배양한 후, 상층액을 제거한 후 100% DMSO 100uL를 처리하여 형성된 formazan을 녹였다. 그 후 ELISA 기기를 이용하여 540nm에서 흡광도를 측정하여 세포사멸정도를 측정하여 표 1에 결과를 나타내었다.Apoptosis caused by UV irradiation on skin cells was measured using MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H-tetrazolium bromide) reagent. MTT reagent measured the degree of apoptosis by dissolving the formazan formed to form formazan by dehydrogenase of living mitochondria. After culturing the cells, the medium was removed after irradiating UV light and culturing for a certain period of time. Thereafter, MTT at a final concentration of 0.5 mg/mL was dissolved in PBS and treated. After incubation at 37 ° C. for 4 hours, the supernatant was removed and the formazan formed by treatment with 100 uL of 100% DMSO was dissolved. Thereafter, the absorbance was measured at 540 nm using an ELISA device to measure the degree of apoptosis, and the results are shown in Table 1.
IC50(mg/ml)ORAC assay
IC50 (mg/ml)
IC50(mg/ml)ABTS assay
IC50 (mg/ml)
IC50(mg/ml)DPPH assay
IC50 (mg/ml)
EC50(μg/ml)Protective effect of UVB-treated cell death
EC50 (μg/ml)
ROS generation
IC50(μg/ml)Inhibitory effect of UVB-treated
ROS generation
IC50 (μg/ml)
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200181700A KR20220090815A (en) | 2020-12-23 | 2020-12-23 | Composition for preventing or improving skin cell damage caused by ultraviolet rays containing Symplocos chinensis f. pilosa (Nakai) Ohwi fruits extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200181700A KR20220090815A (en) | 2020-12-23 | 2020-12-23 | Composition for preventing or improving skin cell damage caused by ultraviolet rays containing Symplocos chinensis f. pilosa (Nakai) Ohwi fruits extracts |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20220090815A true KR20220090815A (en) | 2022-06-30 |
Family
ID=82215065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200181700A KR20220090815A (en) | 2020-12-23 | 2020-12-23 | Composition for preventing or improving skin cell damage caused by ultraviolet rays containing Symplocos chinensis f. pilosa (Nakai) Ohwi fruits extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20220090815A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101132040B1 (en) | 2011-04-18 | 2012-04-02 | (주)프론트바이오 | Composition for alalgesic or neurophatic pain comprising extract of symplocos chinensis for. pilosa or its leaf |
KR20200086207A (en) | 2019-01-08 | 2020-07-16 | 서울대학교산학협력단 | Composition for prevention or treatment of diabetic related disease comprising extract of Symplocos spp. or compound isolated from thereof |
-
2020
- 2020-12-23 KR KR1020200181700A patent/KR20220090815A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101132040B1 (en) | 2011-04-18 | 2012-04-02 | (주)프론트바이오 | Composition for alalgesic or neurophatic pain comprising extract of symplocos chinensis for. pilosa or its leaf |
KR20200086207A (en) | 2019-01-08 | 2020-07-16 | 서울대학교산학협력단 | Composition for prevention or treatment of diabetic related disease comprising extract of Symplocos spp. or compound isolated from thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8663712B2 (en) | Bioactive botanical cosmetic compositions and processes for their production | |
US8668939B2 (en) | Bioactive botanical cosmetic compositions and processes for their production | |
KR101728686B1 (en) | Cosmetic composition containing snail mucus fed with berry and fruit priducing method thereof | |
KR102525467B1 (en) | Skin external application composition for anti-aging containing Rhodotypos scandens extract | |
WO2018097388A1 (en) | Composition for skin whitening, wrinkle alleviation, antioxidation, and ultraviolet light blocking, containing jujube seed extract as active ingredient | |
KR100898307B1 (en) | Cosmetic composition with the antioxidant effect protecting skins aging | |
KR101656928B1 (en) | Composition for protecting skin against UV light and wrinkle improvement comprising the extract of Polygonum viscoferum | |
KR101027113B1 (en) | Method for cosmetic composition containing pine endodermis extract from Pinus thunbergii Parl. | |
KR20220090815A (en) | Composition for preventing or improving skin cell damage caused by ultraviolet rays containing Symplocos chinensis f. pilosa (Nakai) Ohwi fruits extracts | |
KR20080108065A (en) | Manufacturing method of cometic compositions containing extract of paeonia suffruticosa andrew | |
KR20080098925A (en) | Cometic compositions containing extract of paeonia suffruticosa andrew | |
KR20220090814A (en) | Composition for preventing or improving skin cell damage caused by ultraviolet rays containing Wisteria floribunda (Willd.) DC. seed extracts | |
KR100552269B1 (en) | A cosmetic composition containing extract of Campsis grandiflora and/or Torreya nucifera seed | |
KR100472122B1 (en) | Anti-aging cosmetics composition containing Phenolic compound | |
KR101398392B1 (en) | cosmetic compositions containing extract of Viburnum dilatatum Thunb used for antiwrinkle | |
KR20200046674A (en) | A composition for antioxidating, whitening and improving wrinkle comprising extracts of black persimmon | |
JP5425413B2 (en) | Elastase inhibitor | |
KR20010018657A (en) | A cosmetic composition containing Sophorae Flos extracts | |
KR100983526B1 (en) | A cosmetic composition containing Cupressus funebris extract | |
WO2003063803A1 (en) | Bioactive botanical cosmetic ingredients and processes for their production | |
KR20210070508A (en) | Polyphenolic grape extract and cosmetic product comprising said extract | |
KR20230099796A (en) | Cosmetic composition for protecting photo-damaged skin comprising a fraction of Ginseng Berry extract | |
KR20240079253A (en) | A composition for preventing uv-induced skin damage comprising prunus yedonesis extract | |
KR20230173287A (en) | A cosmetic composition comprising rucinol and natural extracts for skin-whitening | |
KR20010018664A (en) | A cosmetic composition containing Alpiniae katsumadai Hayata extracts |